Compare WEYS & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | ACHV |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 239.0M |
| IPO Year | N/A | N/A |
| Metric | WEYS | ACHV |
|---|---|---|
| Price | $30.32 | $5.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 15.0K | ★ 577.5K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $279,843,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.51 | $1.84 |
| 52 Week High | $37.25 | $5.78 |
| Indicator | WEYS | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 67.56 |
| Support Level | $30.13 | $4.30 |
| Resistance Level | $31.82 | $5.28 |
| Average True Range (ATR) | 0.95 | 0.27 |
| MACD | -0.22 | 0.09 |
| Stochastic Oscillator | 25.29 | 95.38 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.